This clinical study (n=54) found that ketamine was well tolerated as a treatment for depression, although anti-depressant effects were smaller than in previous studies.
Introduction
Ketamine has emerged as a rapid-acting antidepressant, though controversy remains regarding whether sufficient data exist to justify its use outside of research protocols. In October 2014, our institution began providing ketamine as an off-label therapy for patients not able to participate in research protocols on a case-by-case basis. Here we describe our experience over 30 months providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.
Method
Initially, patients were treated with a single- or double-infusion protocol (0.5mg/kg over 40 minutes intravenously). We later transitioned to a 4-infusion protocol over two weeks.
Results
Overall, 54 patients have received ketamine at our institution, with 518 total infusions performed. A subset of 44 patients with mood disorders initiated the four-infusion protocol, of which 45.5% responded and 27.3% remitted by the 4th infusion. A subsample (N=14) have received ketamine on a long-term basis, ranging from 12 to 45 total treatments, over a course of 14 to 126 weeks. We found no evidence of cognitive decline, increased proclivity to delusions, or emergence of symptoms consistent with cystitis in this subsample.
Conclusion
In general, ketamine infusions have been tolerated well. The response and remission rates in our clinical sample were lower than those observed in some research protocols. The small number of patients who have been treated on a maintenance schedule limits the conclusions that can be drawn regarding long-term safety of ketamine, however no long-term adverse effects have been observed in our sample.
Papers cited by this study that are also in Blossom
Sos, P., Klirova, M., Novák, T. et al. · Neuropsychiatric Disease And Treatment (2013)
Zarate, C. A., Brutsche, N. E., Ibrahim, L. et al. · Biological Psychiatry (2012)
Singh, J. B., Fedgchin, M., Daly, E. J. et al. · American Journal of Psychiatry (2016)
Murrough, J. W., Perez, A. M., Pillemer, S. et al. · Biological Psychiatry (2012)
In total, 54 patients were treated with one or more ketamine infusions from October 2014 through February 2017. In total, 518 infusions were given. Tableshows the demographic and baseline clinical characteristics of these patients. Three patients with schizoaffective disorder were treated. The rationale for one of these patients has been described previously. 25, 26 The other two patients had failed ECT and were suffering from severe functional limitations due to the current depressive episode.
Of 54 total patients treated, 44 patients had a primary mood disorder and began a 4-infusion protocol, with treatment given twice weekly over 2 weeks. Using a self-report measure (QIDS-SR), patients showed a significant reduction in symptoms over time in a general linear, mixed model (main effect of time, t=-9.40, p<0.001; Figure). Overall, QIDS-SR scores decreased from 16.8 to 10.4, a 37.9% reduction. The majority of the improvement (64.7% of total improvement, or a reduction of 4.12 QIDS-SR points) occurred between the first and second infusions (a 2-4 day time-period). MADRS data was collected on 36 of these subjects and showed a similar pattern (Figure), with a significant effect of time in a general linear, mixed model (t=-8.48, p<0.001). Overall, MADRS scores decreased from 32.8 to 20.4, a 37.8% reduction. The majority of improvement (68.5% of total improvement, or a reduction of 8.5 MADRS points) occurred between the first and second infusions. Using a general linear, mixed model, we adjusted for peak CADSS (at 40 minutes), age, gender, and history of failed ECT. None of these variables moderated the effect of time using the MADRS or QIDS scores.
We calculated dichotomous outcomes from the sample of patients with mood disorders who began a 4-infusion protocol (N=44). Following the first infusion, 31.7% of patients were classified as responders (50% or greater improvement in QIDS-SR). By the 4 th infusion, 45.5% of patients were responders. Prior to our instituting a 4-infusion protocol, we treated 6 patients with mood disorders with single-or double-infusion protocols. Of these 6, 5 experienced a 50% improvement in mood symptoms following the first treatment. Hence, 50.0% of patients with mood disorders responded to a protocol of infusions ranging from 1 to 4. Following a single infusion, 11.3% of patients were classified as remitters (QIDS-SR ≤ 5); following 4 infusions, 27.3% of patients were classified as remitters. Using MADRS data on a smaller sample (N=36), 22.2% of patients responded following the first infusion. By the 4 th infusion, 38.9% responded. We did not perform MADRS assessments for the 6 patients with mood disorders treated before we instituted a 4-infusion protocol. Following a single infusion, 13.9% of patients remitted (MADRS ≤ 10); by the 4 th infusion, 25.0% of patients remitted.
Of the 44 patients with mood disorders who began the 4-infusion protocol, 5 did not complete all treatments. Reasons for discontinuation were lack of efficacy (4) and lack of tolerability of infusions (1). Of the 518 total infusions (N=54), two were discontinued midinfusion. In a 48-year-old female with MDD, type I diabetes and hypertension, the first infusion was stopped early due to elevated blood pressure (max 181/72). Within 10 minutes of stopping the infusion, blood pressure was 168/69, and by 30 minutes was 149/64. This subject received low-dose oral labetalol (50-100mg) pre-treatment prior to subsequent infusions with good effect (max blood pressures of 161/79, 141/61, and 152/69 for the 2 nd , 3 rd , and 4 th infusions, respectively). The subject experienced a remission following the first infusion. The other early termination occurred during the first infusion of a 78-year-old female with MDD who was hospitalized. The infusion was stopped 10 minutes early due to intolerable dissociative side effects. The patient was able to tolerate all 3 subsequent infusions but did not show clinical improvement. Of the 54 patients who received ketamine, 16 (29.6%) experienced mild nausea and received prophylactic ondansetron for subsequent infusions. No patient vomited during treatment. Two patients (3.7%) received pre-treatment, low-dose oral labetalol prophylactically based on blood pressure elevations during prior treatments.
Figureshows long-term outcomes over two years for all patients (N=14) from our program who have received continuation/maintenance ketamine treatments for at least 14 weeks.Overall, these patients have received 351 treatments, with an average treatment per patient of 25.1 (SD 10.5) and a median per patient treatment of 27 (range 10-45). The average length of course of therapy among these patients is 75.7 (SD 39.2) weeks, with a median of 84 weeks (range 14 -126). Of these 14 patients, 3 initiated therapy on a single-or doubleinfusion protocol. Not including acute course of four treatments given twice per week, the average time between treatments is 22.3 (SD 22.7) days, with the median time between treatments of 21 days (range 2-189). Among the 14 longer-term patients, we observed 1 case of tachyphylaxis. A 16-year-old male with MDD who failed ECT and had recurrent hospitalizations showed remission following four treatments (MADRS was 4 at this time point). After attempting to taper the treatments to every 2 weeks, his MADRS rose to 28. Additional infusions given twice weekly did not lead to clinical improvement. Two patients relapsed resulting in suicide attempts and hospitalizations during long-term follow up. Both were able to regain response status after repeated ketamine course (infusions twice weekly). Seven additional patients relapsed (depression score <25% improvement from baseline) during the two-year follow-up period but were all able to regain response status. One patient relapsed after a 6-month hiatus (living in another state) and was able to regain a partial but not full response to treatment after a repeat acute series of ketamine treatments. Three patients did not relapse during longer-term follow-up. Qualitatively, 7 of these long-term patients report that the antidepressant effect of ketamine starts to fade approximately 3 weeks following exposure.
Among the full sample, the majority of patients (96.3%) were taking one or more psychotropic medications (eAppendix 3). The most common medication type was an antidepressant, taken by 72.2% of patients. This was followed by antipsychotic (53.7%), sedative/hypnotic (50.0%), mood stabilizer/anticonvulsant (37.0%), stimulants (22.2%), and lithium (18.5%). There was no moderating effect of any class of psychotropic medication, including benzodiazepines, on antidepressant effect as measured by MADRS or QIDS-SR. Among the 14 longer-term patients, changes in concomitant medications can be found in the eAppendix 4.
One of our patients, an adolescent with multiple hospitalizations who failed ECT prior to beginning ketamine, was surreptitiously using cannabis on a frequent basis. He had a history of intermittent cannabis use prior to beginning treatment though this was not disclosed. His urine toxicology screen prior to initiating therapy was negative. Upon discovery of his use, further ketamine treatments were contingent upon his abstinence, which he was not able to maintain. Hence ketamine treatments were discontinued. Two patients who received treatment later committed suicide. One experienced significant clinical improvement after 4 treatments given over 2 weeks. She received one maintenance treatment 2 months following the acute course of treatments but no further ketamine treatments following this. She committed suicide by hanging 4 months after her last dose of ketamine. Another patient committed suicide by hanging approximately 10 months after receiving his final ketamine treatment. He had been seen in psychiatric follow up the week of his death and had been in a heated argument with an ex-spouse the day of his suicide. He had experienced a partial improvement from the ketamine following 4 treatments (35.6% improvement).
Following the first treatment, the mean CADSS scores at 40 minutes was 6.79 (SD 8.51), and had nearly returned to zero at 70-80 minutes (mean score 0.12, SD 0.32). Following the 2 nd , 3 rd , and 4 th infusions, CADSS scores at 40 minutes were 5.86 (SD 6.25), 4.52 (SD 5.03), and 4.53 (SD 7.16), respectively. Following the 2 nd , 3 rd , and 4 th infusions, mean CADSS scores at 70-80 minutes were 0.07 (SD 0.26), 0.04 (SD 0.19), and 0.00 (SD 0.00), respectively.
Collapsing data across the 4 acute infusions, mean systolic blood pressure (SBP) increased from baseline of 123.3 (SD 16.6) to a peak of 133.5 (SD 19.0) at 50 min (10 min following completion of infusion). By 70 min, mean SBP was 127.9 (SD 15.6) (Figure). Mean diastolic blood pressure (DBP) increased from 73.8 (SD 9.6) at baseline to a peak of 77.6 (SD 10.8) at 40 min. By 70 min, mean DBP was 75.6 (SD 12.5). Mean heart rate remained between 75 and 78 beats per minute (SD 13.3-13.8) throughout the infusion and recovery time. Mean pulse oximetry readings ranged from 98.1-98.4% (SD 1.5-2.0) throughout the infusion period and recovery time. Five patients experienced SBP elevated over 180 during their first infusion, though 4 of these were transient. One patient consistently had a SBP of 180 or greater at the last time point (40 minutes) of his second, third, and fourth infusions, which normalized within 30 minutes following treatment. During the first infusion, one patient transiently had a DBP of 110, which normalized within 30 minutes post-infusion. No patient had DBP values of 110 or greater during the second, third, or fourth infusions.
Among the subsample of patients receiving ketamine long-term (N=14), there was no correlation between number of treatments received and paired change in cognitive measures of attention, processing speed, working memory, verbal memory, and visual memory (Table). The average paired difference for each domain was positive, except for the measure of attention. The median time between assessments was 331 days (range 49-522 days). Among the full sample, baseline measures of cognition did not correlate with improvement in depressive symptoms.
From October 2014 through February 2017, our service provided ketamine as a clinical treatment to 54 patients, 14 of whom have received long-term infusions of 12 treatments or more. Infusions given at 0.5mg/kg over 40 minutes are generally well tolerated, with one patient requiring premature cessation of infusion prior to completion due to intolerable dissociative effects, and one for transient hypertension. Notably, our response (50%) and remission (27.3%) rates following a 4-infusion protocol are lower than those reported in most clinical trials.We found no effect of acute dissociative symptoms, age, gender, and history of failed or inability to tolerate ECT on response. Among the subsample receiving long-term treatment, there was no correlation between number of infusions and change in cognition. Many potential reasons exist for the discrepancy between the relatively lower rates of response and remission in this sample compared to research settings. There is often an "efficacy-effectiveness" gap as new treatments move from research to clinical settings.Considerably less attention is paid to patients outside of research protocols compared to research subjects. Part of the large effect of ketamine observed in research trials may be due to these non-specific, supportive effects. Randomized trials with ketamine compared to saline placebo may also result in artificially large effect sizes due to functional unblinding because of psychoactive properties of the drug. Compared to samples from prior research trials, our patient sample may also represent a more ill and complicated population. As noted above, most of the subjects receiving open-label clinical treatment in our program were considered for clinical trial enrollment but were not appropriate for participation for various reasons, including disallowed comorbid conditions (general medical and/or psychiatric), evidence of ultra-refractoriness (failing numerous previous treatment trials and/or ECT), current hospitalization, inability to delay treatment long enough to complete required study procedures (medication washout, observation periods), presence of significant suicidal ideation or behavior, and age outside of protocol limits. As one example, almost 40% of our patients began treatment as inpatients. Whereas some research protocols required patients to be hospitalized overnight as part of the research protocol,the hospitalized patients from our sample were admitted for clinical reasons of suicide risk or inability to function. Nonetheless, in this sample of complicated and severely ill patients (55.1% who had failed or not tolerated ECT and 38.9% who were inpatients), we feel a 50% response rate within 2 weeks of treatment is a significant outcome. While we did not document potential adverse events with the same level of scrutiny afforded in sponsored clinical trials, we did not observe gross decrements in cognition, an increased propensity for delusions, or emergent symptoms indicative of cystitis over time. Beyond the one adolescent with continued cannabis use, we saw no evidence of patients showing signs of substance abuse or increased drug seeking in our sample of patients. It should be emphasized, however, that our sample of patients receiving long-term treatment (N=14) is very small and does not provide statistical power sufficient to detect subtle changes in cognition, delusions, or bladder function. The field urgently awaits further and more powerful long-term safety data on ketamine and related compounds. Overall, in the 30-month history of our program, two former patients committed suicide. One did so 10 months following last contact with our program and was judged not to be related to ketamine treatment. The other suicide occurred 4 months following last contact with our program. In this case, the patient's health maintenance organization did not refer the patient back to our institution for consideration of further treatment. Both of these patients had a history of hospitalization for suicide attempts. It noteworthy that almost half (46.9%) of the patients in our sample had a history of attempted suicide while nearly twothirds (64.8%) had been hospitalized for suicidal ideation or suicide attempts. In light of this, we believe it is unlikely that ketamine exposure increased their propensity towards suicide, especially given the long period between the time of death and last ketamine exposure. However, given the severity of illness of patients with treatment-resistant depression,these cases highlight the critical need for consideration of longer-term strategies prior to treatment initiation, especially given the lack of long-term data on ketamine use.The small size and racial homogeneity of our sample limits the generalizability of our results. However, given the paucity of data on long-term safety, our results provide the first signal of long-term safety in a small sample. There remains an urgent need for more powerful and comprehensive long-term safety data on ketamine from much larger samples. This need is underscored by the rapid growth in the number of providers offering ketamine outside of research protocols for the treatment of psychiatric disorders.Given that racemic ketamine hydrochloride no longer has patent protections, it is unlikely that large and longterm clinical trials will be conducted to provide such long-term safety data. The formation of a registry combining data from community and academic sites is therefore the most realistic way of capturing long-term data on the effectiveness and safety of ketamine as a treatment for mood disorders.
Ketamine shows promise as a potential treatment for refractory mood disorders; however, evidence to date are mostly limited to short-term outcomes (≤1 month)
The field urgently awaits long-term data on efficacy and safety of ketamine as a treatment for psychiatric disorders
Longer-term treatment strategies should be considered prior to initiation of ketamine as a treatment Vital sign monitoring during and 30 minutes following a 40-minutes infusion protocol of 0.5mg/kg intravenous ketamine. Data represent 54 patients, with 210 total infusions.
Create a free account to open full-text PDFs.
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Sanacora, G., Frye, M. A., McDonald, W. et al. · JAMA Psychiatry (2017)
Papers in Blossom that reference this study
Veraart, J. K. E., Smith-Apeldoorn, S. Y., van der Meij, A. et al. · Journal of Psychopharmacology (2025)
Zhou, Y., Lan, X-F., Wang, C. et al. · Child and Adolescent Psychiatry (2024)
Yonezawa, K., Uchida, H., Yatomi, T. et al. · Pharmacopsychiatry (2023)
Nikolin, S., Rodgers, A., Schwaab, A. et al. · EClinicalMedicine (2023)
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Spijker, J. et al. · Lancet Psychiatry (2022)
Mcinnes, L. A., Qian, J. J., Gargeya, R. S. et al. · Journal of Affective Disorders (2022)
Wilkinson, S. T., Taeho, G., Rhee et al. · Psychotherapy and Psychosomatics (2021)
Davis, M. T., Dellagiogia, N., Maruff, P. et al. · Translational Psychiatry (2021)
Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)